India's 'Pharmacy of the World' Under US Tariff Pressure

India, a critical global supplier of generic medicines, is bracing for potential impacts from proposed US tariffs. As the "pharmacy of the world," India exports approximately $10.5 billion worth of pharmaceuticals to the United States annually, representing a substantial portion of the US generic drug market. Major global drug manufacturers have cautioned that these tariffs could lead to increased medication costs and diminished accessibility for patients.

The US administration has expressed a desire to reduce reliance on overseas drug production, initiating investigations into pharmaceutical imports. This has intensified pressure on generic drug manufacturers to establish or expand their operations within the United States. While some manufacturers of patented medicines have already committed to new investments in US-based production, the tariff roadmap, set to take effect from 2028, places generic drugmakers under greater scrutiny.

Discussions between India and the US are presently ongoing, focusing on negotiated outcomes for generic pharmaceuticals and their key ingredients. The outcome of these trade talks will determine whether Indian manufacturers will receive exemptions or benefit from lower tariff rates. The situation remains dynamic as both nations work towards a resolution.